Biologics, like monoclonal antibodies and viral vectors, make up rapidly growing classes of drugs. They are also critical research tools and essential for the development of many new diagnostics.
While chromatography has been a mainstay of small molecules, these larger, bulky biologics require a new approach to downstream manufacturing. Isolere Bio was founded with the vision of simplifying and streamlining the purification of biotherapeutics to improve global access to these important drugs.
We are currently focused on developing this technology for the manufacturing of antibodies and adeno-associated virus (AAV). We are working to develop a low-cost, high throughput, and scalable purification platform and are actively seeking research collaborators in development and validation.
Our product is made entirely recombinantly in E. coli and has no synthetic scaffold. This eliminates the cost of the solid support and chemical conjugation.
Our process scales linearly, providing a seamless transition from bench to industry scale production.
EASE OF USE
Our technology requires a simple tangential flow filtration (TFF) setup rather than complex chromatography equipment.
From high throughput 96-well plates, to all-in-one kits, to bulk reagent, our technology can be tailored to suit your needs.
Complete an entire round of purification with TFF in under 30 minutes! High flux will eliminate the capture step bottleneck and permeate control enables seamless development of a continuous downstream processes.
Our reagent binds and elutes the target in solution, eliminating the mass transfer constraints of traditional packed bed chromatography
Chromatography-free solutions for the purification of biological therapeutics such as monoclonal antibodies and viral gene delivery vectors.
Isolere begins working on IP strategy with Mike Tuscan and Erin Foley at Cooley, LLC. Isolere begins consulting with TFF expert, John Rozembersky.
Michael Dzuricky joins the management team as our new CSO and Steve Docksey begins as a Strategic Advisor. Welcome!
Isolere is awarded a Strategic Research Loan from the NC Biotech Center.
Isolere receives Phase II SBIR funding from the National Institutes of Health.
Welcome to the R&D Team, JB Jones!
THE ISOTAG TECHNOLOGY
This process is highly platform-able! Contact us to discuss custom reagent development to your therapeutic of interest. By replacing the antibody-binding domain with a different capture domain at the gene level, this versatile technology can be applied to other biotherapeutics.
FOUNDER & CHAIRMAN OF THE BOARD
Michael Dzuricky, PhD
CHIEF SCIENTIFIC OFFICER
Ashutosh Chilkoti, PhD
FOUNDER & CHIEF SCIENTIFIC ADVISOR
Kelli Luginbuhl, PhD
FOUNDER & CHIEF EXECUTIVE OFFICER